Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZYXI 
Zynex Inc (ZYXI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ZYXI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -42.02% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.96M USD | Price to earnings Ratio 27.56 | 1Y Target Price 15 |
Price to earnings Ratio 27.56 | 1Y Target Price 15 | ||
Volume (30-day avg) 359116 | Beta 0.81 | 52 Weeks Range 2.14 - 12.84 | Updated Date 04/1/2025 |
52 Weeks Range 2.14 - 12.84 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.56% | Operating Margin (TTM) -1.23% |
Management Effectiveness
Return on Assets (TTM) 2.89% | Return on Equity (TTM) 7.32% |
Valuation
Trailing PE 27.56 | Forward PE 16.61 | Enterprise Value 100693178 | Price to Sales(TTM) 0.39 |
Enterprise Value 100693178 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.52 | Enterprise Value to EBITDA 9.33 | Shares Outstanding 30227400 | Shares Floating 18788158 |
Shares Outstanding 30227400 | Shares Floating 18788158 | ||
Percent Insiders 48.18 | Percent Institutions 28.12 |
Analyst Ratings
Rating 4.33 | Target Price 17.5 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zynex Inc
Company Overview
History and Background
Zynex Inc. was founded in 1996. Initially focused on distribution, it transitioned to designing and manufacturing its own medical devices for pain management and rehabilitation. The company has grown through product innovation and strategic acquisitions.
Core Business Areas
- Pain Management Devices: Design, manufacture, and market electrotherapy medical devices used for pain management. These devices deliver non-invasive electrical stimulation to reduce pain and improve function.
- Rehabilitation Devices: Offer devices for rehabilitation and recovery following injury or surgery, aiding in muscle re-education and strengthening.
- Monitoring Solutions: Develop and offer blood volume monitoring systems for use in hospitals. Marketed as CM-1500.
Leadership and Structure
Thomas Sandgaard serves as the Chairman, President, and CEO. The company operates with a functional organizational structure, encompassing R&D, manufacturing, sales & marketing, and administrative functions.
Top Products and Market Share
Key Offerings
- NeuroMove: A device used to treat stroke patients that suffer from foot drop. Competitors include Bioness and Intento.
- EvoStim System: An electrotherapy device for pain relief and muscle rehabilitation. The competitors are NeuroMetrix and DJO Global.
- CM-1500: A blood volume monitoring system primarily for hospital use. Competitors include ICU Medical and Baxter International.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and competition. Demand for pain management and rehabilitation devices is driven by an aging population, increasing incidence of chronic pain, and a growing emphasis on non-pharmacological treatments.
Positioning
Zynex Inc. positions itself as a provider of innovative and effective medical devices for pain management and rehabilitation, offering alternatives to opioids and invasive procedures.
Total Addressable Market (TAM)
The TAM for pain management devices is estimated to be in the billions of dollars. Zynex is capturing a fraction of this market, indicating potential for growth.
Upturn SWOT Analysis
Strengths
- Proprietary technology and patents
- Direct sales force
- Vertically integrated manufacturing
- Focus on non-opioid pain management
Weaknesses
- Reliance on a few key products
- High sales and marketing expenses
- Susceptibility to reimbursement changes
- Dependence on direct sales model for growth
Opportunities
- Expanding product line
- Entering new geographic markets
- Acquiring complementary businesses
- Capitalizing on the opioid crisis
Threats
- Increased competition
- Changes in healthcare regulations
- Product liability claims
- Economic downturns
Competitors and Market Share
Key Competitors
- NTRX
- DJCO
- BXRX
Competitive Landscape
Zynex Inc. competes with other medical device companies in the pain management and rehabilitation markets. Its advantages include proprietary technology and a direct sales force. Disadvantages include reliance on a few key products and high sales expenses.
Major Acquisitions
Kestrel Labs
- Year: 2021
- Acquisition Price (USD millions): 33
- Strategic Rationale: Acquisition of Kestrel Labs to offer blood volume monitoring devices for hospital use. Marketed as CM-1500.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced growth driven by increased sales of its pain management devices and strategic acquisitions.
Future Projections: Analyst estimates project continued growth in revenue and earnings, driven by increasing demand for non-opioid pain management solutions.
Recent Initiatives: Recent initiatives include product development, expansion of the sales force, and strategic acquisitions.
Summary
Zynex shows good financial strength through innovation in niche products, sales team structure, and acquisitions. The company is susceptible to external conditions such as changes in healthcare regulations, and product liability claims. The company should maintain and grow revenue through its direct sales team, while continuing to innovate new product lines and acquire firms to strengthen its offerings.
Similar Companies
- NTRX
- DJCO
- BXRX
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports, third-party market research
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zynex Inc
Exchange NASDAQ | Headquaters Englewood, CO, United States | ||
IPO Launch date 2002-12-31 | Founder, President, CEO & Chairman Mr. Thomas Sandgaard | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1000 | Website https://www.zynex.com |
Full time employees 1000 | Website https://www.zynex.com | ||
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.